Millipore Sigma Vibrant Logo
Attenzione: Ci siamo trasferiti. Non è più possibile acquistare i prodotti Merck Millipore nel sito MerckMillipore.comPer saperne di più

345670 Galanthamine, Hydrobromide - CAS 69353-21-5 - Calbiochem

345670
Purchase on Sigma-Aldrich

Panoramica

Replacement Information

Tabella delle specifiche principali

CAS #Empirical Formula
69353-21-5C₁₇H₂₁NO₃ · HBr

Products

Numero di catalogoConfezionamento Qtà/conf
345670-20MG 20 mg
Description
OverviewA competitive and reversible inhibitor of acetylcholinesterase. Antimyasthenic agent. Can partially reverse the effects of scopolamine-induced amnesia in rats. Reported to improve learning and short-term memory in animal models.
Catalogue Number345670
Brand Family Calbiochem®
SynonymsNivalin, HBr
References
ReferencesPilger, C., et al. 2001. J. Mol. Graph. Model 19, 288.
Iliev, A., et al. 1999. Methods Find. Exp. Clin. Pharmacol. 21, 297.
Southan, G.J., et al. 1996. Br. J. Pharmacol. 117, 619.
Mutafova-Yambolieva, V.N., et al. 1993. Gen. Pharmacol. 24, 1253.
Product Information
CAS number69353-21-5
ATP CompetitiveY
FormWhite solid
Hill FormulaC₁₇H₂₁NO₃ · HBr
Chemical formulaC₁₇H₂₁NO₃ · HBr
ReversibleY
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetAcetylcholinesterase
Purity≥95% by HPLC
Physicochemical Information
Cell permeableN
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
RTECSDF8075000
Safety Information
R PhraseR: 25

Toxic if swallowed.
S PhraseS: 22-36/37/39-45

Do not breathe dust.
Wear suitable protective clothing, gloves and eye/face protection.
In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Toxic
Hazardous Materials Attention: Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
Storage +2°C to +8°C
Protect from Moisture Protect from moisture
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Numero di catalogo GTIN
345670-20MG 04055977194494

Documentation

Galanthamine, Hydrobromide - CAS 69353-21-5 - Calbiochem MSDS

Titolo

Scheda di sicurezza (MSDS) 

Galanthamine, Hydrobromide - CAS 69353-21-5 - Calbiochem Certificati d'Analisi

TitoloNumero di lotto
345670

Riferimenti bibliografici

Panoramica delle referenze
Pilger, C., et al. 2001. J. Mol. Graph. Model 19, 288.
Iliev, A., et al. 1999. Methods Find. Exp. Clin. Pharmacol. 21, 297.
Southan, G.J., et al. 1996. Br. J. Pharmacol. 117, 619.
Mutafova-Yambolieva, V.N., et al. 1993. Gen. Pharmacol. 24, 1253.

Brochure

Titolo
Alzheimer's Disease Brochure & Technical Guide
Scheda tecnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision30-March-2010 RFH
SynonymsNivalin, HBr
DescriptionCholinesterase antagonist. Antimyasthenic agent. Can partially reverse the effects of scopolamine-induced amnesia in rats.
FormWhite solid
CAS number69353-21-5
RTECSDF8075000
Chemical formulaC₁₇H₂₁NO₃ · HBr
Structure formulaStructure formula
Purity≥95% by HPLC
SolubilityDMSO (5 mg/ml), Ethanol (1 mg/ml) or H₂O (1 mg/ml)
Storage Protect from moisture
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Toxic
Merck USA index14, 4340
ReferencesPilger, C., et al. 2001. J. Mol. Graph. Model 19, 288.
Iliev, A., et al. 1999. Methods Find. Exp. Clin. Pharmacol. 21, 297.
Southan, G.J., et al. 1996. Br. J. Pharmacol. 117, 619.
Mutafova-Yambolieva, V.N., et al. 1993. Gen. Pharmacol. 24, 1253.